The association has reached an agreement to undertake a strategic collaboration in order to develop a project to study the biology of glucocorticoids in the origin and evolution of Lymphangioleiomyomatosis.
AELAM donates 15.000€ to research on Lymphangioleiomyomatosis Read More »
This finding, published in the International Journal of Antimicrobial Agents, highlights the possibility that this resistance mechanism could spread to other sexually transmitted pathogens.
EATRIS, the European Infrastructure for Translational Medicine, has just announced its participation in the stakeholders’ advisory group in the ‘COMBINE’ project, an initiative aimed at providing clarity and alignment at the interface between clinical trials of investigational medicinal products, performance studies of in vitro diagnostics, and clinical investigations of medical devices. COMBINE is an
The IDIBELL research group on immunoinflammatory processes demonstrates that the C4BP (β-) protein could be a promising therapeutic option for inflammatory bowel disease.
The work has analyzed the interaction of the IKKα protein with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing the toxicity of the treatment.
The group has applied these classification recommendations to 128 variants reported in the literature and/or public databases, classifying 17 as pathogenic variants, and another 17 as benign.
Genetic studies that initially gave uncertain results can provide a reliable diagnosis if reviewed after two years
This Saturday took place the open day of the fifth edition of Sinergia, the celebration of health research and innovation in L’Hospitalet. More than 300 people came to the Bellvitge Campus to take part in the everyday work of that IDIBELL, the Catalan Institute of Oncology, the Bellvitge University Hospital, the University of Barcelona and the Hospital Sant Joan de Déu do to improve people’s health.
Absolute success of the Sinergia 2023 open day Read More »
A new study carried out by the Nutrition and Cancer research group of IDIBELL and the Catalan Institute of Oncology, with the collaboration of the scientific and technological center AZTI, offers a relevant review and update of data that demonstrates how eating habits and the microbiota intestine could play a key role in cancer prevention.
The new treatment is a drug that eliminates the antibodies that bind to gram-negative bacteria and makes them resistant to destruction by the immune system.
